

U.S. Application No. 09/758,173
Preliminary Amendment dated November 26, 2003
Responsive to the Office Action of May 27, 2003
Attorney ref. no. 037003-0276603

I. AMENDMENT

IN THE SPECIFICATION:

Please replace the title of the application shown on page 1, lines 2-5, with the following rewritten title:

-- METHODS FOR TREATING B CELL LYMPHOMA USING CD80-SPECIFIC ANTIBODIES --

Please replace the paragraph beginning at page 1, line 7, with the following rewritten paragraph:

~~There are no related applications.~~ This is a divisional application of Application No. 09/383,916, filed August 26, 1999, which is a divisional application of Application No. 08/487,550, filed June 7, 1995, which issued as U.S. Patent No. 6,113,898.

Please replace the abstract beginning at page 62, line 2, with the following rewritten abstract:

-- The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies. --

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 21, 25, 27-31, and 33-36 are canceled, and claims 23, 24, 26, 32, and 37 are amended.

1-20. (Previously canceled)

U.S. Application No. 09/758,173
Preliminary Amendment dated November 26, 2003
Responsive to the Office Action of May 27, 2003
Attorney ref. no. 037003-0276603

21. (Newly canceled)

22. (Previously canceled)

23. (Currently amended) A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD80 antibody, The method of claim 21 wherein said antibody binds the same epitope as an anti-B7-1 anti-CD80 antibody selected from the group consisting of 7C10, which has the variable region sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOs 1-2 and 3-4 respectively); 7B6, which has the variable region sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOs. 5-6 and 7-8 respectively); and 16C10, which has the variable region sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively).

24. (Currently amended) The method of claim 23 wherein said ~~anti-B7~~ anti-CD80 antibody binds the same epitope as an ~~anti-B7-1~~ anti-CD80 antibody selected from the group consisting of 16C10, 7C10, 20C9 and 7B6.

25. (Newly canceled)

26. (Currently amended) ~~The method of claim 21~~ A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD80 antibody, wherein said antibody binds the same epitope as an anti-CD80 antibody selected from the group consisting of 7C10, which has the variable region sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOs 1-2 and 3-4 respectively); 7B6, which has the variable region sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOs. 5-6 and 7-8 respectively); and 16C10, which has the variable region sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively),

wherein said antibody is a non-depleting antibody.

27-31. (Newly canceled)

U.S. Application No. 09/758,173
Preliminary Amendment dated November 26, 2003
Responsive to the Office Action of May 27, 2003
Attorney ref. no. 037003-0276603

32. (Currently amended) ~~The method of claim 21~~ A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-CD80 antibody, wherein the antibody is a primatized[®] antibody having the variable region sequences of an anti-~~B7.1~~ anti-CD80 antibody selected from the group consisting of 7C10, which has the variable region sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOs. 1-2 and 3-4, respectively); 7B6, which has the variable region sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOs. 5-6 and 7-8, respectively); and 16C10, which has the variable region sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12 respectively).

33-36. (Newly canceled)

37. (Currently Amended) The method of claim 32 where the antibody is a primatized[®] antibody having the variable region sequences of antibody 16C10 shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOs. 9-10 and 11-12, respectively).